Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

Innocenti, Tommaso; Hanžel, Jurij; Truyens, Marie; Lukáš, Milan; Gordon, Hannah; Cremer, Anneline; Molnár, Tamás; Julsgaard, Mette; Onali, Sara; Todeschini, Alessia; Maria Nardone, Olga; M Noor, Nurulamin; Caprioli, Flavio; Scaldaferri, Franco; Argyriou, Konstantinos; Savarino, Edoardo; Brinar, Marko; Hedin, Charlotte; Vela González, Milagros; Armuzzi, Alessandro; Blesl, Andreas; Aratari, Annalisa; Quadarella, Alessandro; Lorenzo Parigi, Tommaso; Bertani, Lorenzo; Ferracane, Concetta; Uzzan, Mathieu; Michalopoulos, George; De Bernardi, Alice; Η Katsanos, Konstantinos; Balestrieri, Paola; Piñero, Gisela; Κarmiris, Konstantinos; Gutiérrez, Ana; Nikolić, Sara; Felice, Carla; Pugliese, Daniela; Pastras, Ploutarchos; Mocci, Giammarco; Pouillon, Lieven; J. Mantzaris, Gerassimos; Ramos, Laura; José Casanova, María; E. Κoutroubakis, Ioannis; José García, María; Lobatón, Triana; Dragoni, Gabriele; JAKi-SEQ Study Group, The

doi:10.1093/ecco-jcc/jjaf188

Public

Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

Published in Journal of Crohn s and Colitis • Oct 29, 2025

Authors:

Tommaso Innocenti

Jurij Hanžel

Marie Truyens

Abstract

Abstract Background and aims Evidence from rheumatology supports a within-class treatment switch for JAK-inhibitors (JAKi), but data in ulcerative colitis (UC) remain limited. We aimed to assess the effectiveness and safety of initiating a second JAKi in patients with UC previously treated with anot...

Subject

Medicine

Class (philosophy)

Intensive care medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!